The renin–angiotensin system: a possible contributor to migraine pathogenesis and prophylaxis

References

• Lipton RB, Bigal ME, Diamond M, AMPP Advisory Group. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007;68(5):343-9
   PubMed Web of Science ®Google Scholar
• Steiner TJ, Stovner LJ, Birbeck GL. Migraine: the seventh disabler. J Headache Pain 2013;14(1):1
   PubMedGoogle Scholar
• Silberstein SD, Goadsby PJ, Lipton RB. Management of migraine: an algorithmic approach. Neurology 2000;55(9 Suppl 2):S46-52
   PubMed Web of Science ®Google Scholar
• Probstfield JL, O’Brien KD. Progression of cardiovascular damage: the role of renin-angiotensin system blockade. Am J Cardiol 2010;105(1 Suppl):10A-20A
   PubMedGoogle Scholar
• Unger T, Stoppelhaar M. Rationale for double renin-angiotensin-aldosterone system blockade. Am J Cardiol 2007;100(3A):25J-31J
   PubMed Web of Science ®Google Scholar
• Bader M. Tissue renin-angiotensin-aldosterone systems: targets for pharmacological therapy. Ann Rev Pharmacol Toxicol 2010;50:439-65
   PubMed Web of Science ®Google Scholar
• von Bohlen und Halbach O, Albrecht D. The CNS renin-angiotensin system. Cell Tissue Res 2006;326(2):599-616
   PubMedGoogle Scholar
• Gard PR. The role of angiotensin II in cognition and behaviour. Eur J Pharmacol 2002;438(1-2):1-14
   PubMedGoogle Scholar
• Wright JW, Harding JW. Important role for angiotensin III and IV in the brain renin-angiotensin system. Brain Res Brain Res Rev 1997;25(1):96-124
   PubMedGoogle Scholar
• Wright JW, Harding JW. Brain angiotensin receptor subtypes AT1, AT2, and AT4 and their functions. Regul Pept 1995;59(3):269-95
   PubMedGoogle Scholar
• Horiuchi M, Mogi M, Iwai M. The angiotensin II type 2 receptor in the brain. J Renin Angiotensin Aldosterone Syst 2010;11(1):1-6
   PubMedGoogle Scholar
• Lucius R, Gallinat S, Rosenstiel P, et al. The angiotensin II type 2 (AT2) receptor promotes axonal regeneration in the optic nerve of adult rats. J Exp Med 1998;188(4):661-70
   PubMedGoogle Scholar
• Wright JW, Reichert JR, Davis CJ, Harding JW. Neural plasticity and the brain renin-angiotensin system. Neurosci Biobehav Rev 2002;26(5):529-52
   PubMedGoogle Scholar
• Wright JW, Harding JW. Brain renin-angiotensin-a new look at an old system. Prog Neurobiol 2011;95(1):49-67
   PubMed Web of Science ®Google Scholar
• Mertens B, Vanderheyden P, Michotte Y, Sarre S. The role of the central renin-angiotensin system in Parkinson’s disease. J Renin Angiotensin Aldosterone Syst 2010;11(1):49-56
   PubMedGoogle Scholar
• Bender WI. ACE inhibitors for prophylaxis of migraine headaches. Headache 1995;35(8):470-1
   PubMedGoogle Scholar
• Charles JA, Jotkowitz S, Byrd LH. Prevention of migraine with olmesartan in patients with hypertension/prehypertension. Headache 2006;46(3):503-7
   PubMedGoogle Scholar
• Diener HC, Gendolla A, Feuersenger A, et al. Telmisartan in migraine prophylaxis: a randomized, placebo-controlled trial. Cephalalgia 2009;29(9):921-7
   PubMedGoogle Scholar
• Schrader H, Stovner LJ, Helde G, et al. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study. BMJ 2001;322(7277):19-22
   PubMedGoogle Scholar
• Schuh-Hofer S, Flach U, Meisel A, et al. Efficacy of lisinopril in migraine prophylaxis: an open label study. Eur J Neurol 2007;14(6):701-3
   PubMedGoogle Scholar
• Sicuteri F. Enkephalinase inhibition relieves pain syndromes of central dysnociception (migraine and related headache). Cephalalgia 1981;1(4):229-32
   PubMedGoogle Scholar
• Sonbolestan SA, Heshmat K, Javanmard SH, Saadatnia M. Efficacy of enalapril in migraine prophylaxis: a randomized, double-blind, placebo-controlled trial. Int J Prev Med 2013;4(1):72-7
   PubMedGoogle Scholar
• Stovner LJ, Linde M, Gravdahl GB, et al. A comparative study of candesartan versus propranolol for migraine prophylaxis: a randomized, triple-blind, placebo- controlled, double cross-over study. Cephalalgia 2013;34(7):523-32
   PubMedGoogle Scholar
• Tronvik E, Stovner LJ, Helde G, et al. Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. JAMA 2003;289(1):65-9
   PubMed Web of Science ®Google Scholar
• Sacco S, Ripa P, Grassi D, et al. Peripheral vascular dysfunction in migraine: a review. J Headache Pain 2013;14:80
   PubMed Web of Science ®Google Scholar
• D’Amico D, Ferraris A, Leone M, et al. Increase plasma nitrites in migraine and cluster headache patients in intercritical period: basal hyperactivity of L-arginine-NO pathway? Cephalalgia 2002;22(1):33-6
   PubMed Web of Science ®Google Scholar
• Olesen J. The role of nitric oxide (NO) in migraine, tension-type headache and cluster headache. Pharmacol Ther 2008;120(2):157-71
   PubMed Web of Science ®Google Scholar
• Reuter U, Chiarugi A, Bolay H, Moskowitz MA. Nuclear factor-kappaB as a molecular target for migraine therapy. Ann Neurol 2002;51(4):507-16
   PubMed Web of Science ®Google Scholar
• Wolf G, Wenzel U, Burns KD, et al. Angiotensin II activates nuclear transcription factor-kappa B through AT1 and AT2 receptors. Kidney Int 2002;61(6):1986-95
   PubMed Web of Science ®Google Scholar
• Zimmerman MC, Lazartigues E, Sharma RV, Davisson RL. Hypertension caused by angiotensin II infusion involves increased superoxide production in the central nervous system. Circ Res 2004;95(2):210-16
   PubMedGoogle Scholar
• Fusayasu E, Kowa H, Takeshima T, et al. Increased plasma substance P and CGRP levels, and high ACE activity in migraineurs during headache-free periods. Pain 2007;128(3):209-14
   PubMed Web of Science ®Google Scholar
• Levy D, Burstein R, Strassman AM. Mast cell involvement in the pathophysiology of migraine headache: a hypothesis. Headache 2006;46(Suppl 1):S13-18
   Google Scholar
• Ba’albaki H, Rapoport A. Mast cells activate the renin angiotensin system and contribute to migraine: a hypothesis. Headache 2008;48(10):1499-505
   PubMedGoogle Scholar
• Kennedy S, Wu J, Wadsworth RM, et al. Mast cells and vascular disease. Pharmacol Ther 2013;138(1):53-65
   PubMedGoogle Scholar
• He A, Shi GP. Mast cell chymase and tryptase as targets for cardiovascular and metabolic diseases. Curr Pharm Des 2013;19(6):1114-25
   PubMedGoogle Scholar
• Levy D. Migraine pain, meningeal inflammation, and mast cells. Curr Pain Headache Rep 2009;13(3):237-40
   PubMed Web of Science ®Google Scholar
• Sheftell F, Rapoport A, Weeks R, et al. Montelukast in the prophylaxis of migraine: a potential role for leukotriene modifiers. Headache 2000;40(2):158-63
   PubMed Web of Science ®Google Scholar
• Hasselblatt M, Kohler J, Volles E, Ehrenreich H. Simultaneous monitoring of endothelin-1 and vasopressin plasma levels in migraine. Neuroreport 1999;10:423-5
   PubMed Web of Science ®Google Scholar
• Harrison S, Geppetti P, Substance P. Int J Biochem Cell Biol 2001;33(6):555-76
   PubMed Web of Science ®Google Scholar
• Messlinger K, Lennerz JK, Eberhardt M, Fischer MJ. CGRP and NO in the trigeminal system: mechanisms and role in headache generation. Headache 2012;52(9):1411-27
   PubMedGoogle Scholar
• Frei N, Weissenberger J, Beck-Sickinger AG, et al. Immunocytochemical localization of angiotensin II receptor subtypes and angiotensin II with monoclonal antibodies in the rat adrenal gland. Regul Pept 2001;101(1-3):149-55
   PubMedGoogle Scholar
• Hou M, Uddman R, Tajti J, Edvinsson L. Nociceptin immunoreactivity and receptor mRNA in the human trigeminal ganglion. Brain Res 2003;964(2):179-86
   PubMedGoogle Scholar
• Lazarov NE. Comparative analysis of the chemical neuroanatomy of the mammalian trigeminal ganglion and mesencephalic trigeminal nucleus. Prog Neurobiol 2002;66(1):19-59
   PubMedGoogle Scholar
• Imboden H, Patil J, Nussberger J, et al. Endogenous angiotensinergic system in neurons of rat and human trigeminal ganglia. Regul Pept 2009;154(1-3):23-31
   PubMedGoogle Scholar
• Patil J, Schwab A, Nussberger J, et al. Intraneuronal angiotensinergic system in rat and human dorsal root ganglia. Regul Pept 2010;162(1-3):90-8
   PubMedGoogle Scholar
• Diz DI, Block CH, Barnes KL, Ferrario CM. Correlation between angiotensin II binding sites and substance P in the canine brain stem. J Hypertens Suppl 1986;4(6):S468-71
   Google Scholar
• Kopp UC, Cicha MZ, Smith LA. Angiotensin blocks substance P release from renal sensory nerves by inhibiting PGE2-mediated activation of cAMP. Am J Physiol Renal Physiol 2003;285(3):F472-83
   Google Scholar
• Harada N, Shimozawa N, Okajima K. AT(1) receptor blockers increase insulin-like growth factor-I production by stimulating sensory neurons in spontaneously hypertensive rats. Transl Res 2009;154(3):142-52
   PubMedGoogle Scholar
• Marques-Lopes J, Pinto M, Pinho D, et al. Microinjection of angiotensin II in the caudal ventrolateral medulla induces hyperalgesia. Neuroscience 2009;158(4):1301-10
   PubMedGoogle Scholar
• Pelegrini-da-Silva A, Martins AR, Prado WA. A new role for the renin-angiotensin system in the rat periaqueductal gray matter: angiotensin receptor-mediated modulation of nociception. Neuroscience 2005;132(2):453-63
   PubMedGoogle Scholar
• Yien HW, Chan JY, Tsai HF, et al. Participation of nucleus reticularis gigantocellularis in the antinociceptive effect of angiotensin III in the rat. Neurosci Lett 1993;159(1-2):9-12
   PubMedGoogle Scholar
• Nemoto W, Nakagawasai O, Yaoita F, et al. Angiotensin II produces nociceptive behavior through spinal AT1 receptor-mediated p38 mitogen-activated protein kinase activation in mice. Mol Pain 2013;9(1):38
   PubMedGoogle Scholar
• Clasen R, Schupp M, Foryst-Ludwig A, et al. PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin. Hypertension 2005;46(1):137-43
   PubMed Web of Science ®Google Scholar
• Schupp M, Janke J, Clasen R, et al. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004;109(17):2054-7
   PubMed Web of Science ®Google Scholar
• Erbe DV, Gartrell K, Zhang YL, et al. Molecular activation of PPARgamma by angiotensin II type 1-receptor antagonists. Vascul Pharmacol 2006;45(3):154-62
   PubMed Web of Science ®Google Scholar
• García-Bueno B, Madrigal JL, Lizasoain I, et al. Peroxisome proliferator-activated receptor gamma activation decreases neuroinflammation in brain after stress in rats. Biol Psychiatry 2005;57(8):885-94
   PubMedGoogle Scholar
• Moreno S, Farioli-Vecchioli S, Cerù MP. Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS. Neuroscience 2004;123(1):131-45
   PubMed Web of Science ®Google Scholar
• Victor NA, Wanderi EW, Gamboa J, et al. Altered PPARgamma expression and activation after transient focal ischemia in rats. Eur J Neurosci 2006;24(6):1653-63
   PubMedGoogle Scholar
• Hasegawa-Moriyama M, Kurimoto T, Nakama M, et al. Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone attenuates inflammatory pain through the induction of heme oxygenase-1 in macrophages. Pain 2013;154(8):1402-12
   PubMedGoogle Scholar
• Rigat B, Hubert C, Alhenc-Gelas F, et al. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990;86(4):1343-6
   PubMed Web of Science ®Google Scholar
• Tiret L, Rigat B, Visvikis S, et al. Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. Am J Hum Genet 1992;51(1):197-205
   PubMed Web of Science ®Google Scholar
• Sharma P. Meta-analysis of the ACE gene in ischaemic stroke. J Neurol Neurosurg Psychiatry 1998;64(2):227-30
   PubMed Web of Science ®Google Scholar
• Lea RA, Ovcaric M, Sundholm J, et al. Genetic variants of angiotensin converting enzyme and methylenetetrahydrofolate reductase may act in combination to increase migraine susceptibility. Brain Res Mol Brain Res 2005;136(1-2):112-17
   PubMedGoogle Scholar
• Schürks M, Rist PM, Kurth T. MTHFR 677C->T and ACE D/I polymorphisms in migraine: a systematic review and meta-analysis. Headache 2010;50(4):588-99
   PubMedGoogle Scholar
• Pizza V, Agresta A, Agresta A, et al. Migraine and genetic polymorphisms: an overview. Open Neurol J 2012;6:65-70
   PubMedGoogle Scholar
• Paterna S, Di Pasquale P, D’Angelo A, et al. Angiotensin-converting enzyme gene deletion polymorphism determines an increase in frequency of migraine attacks in patients suffering from migraine without aura. Eur Neurol 2000;43(3):133-6
   PubMed Web of Science ®Google Scholar
• Kowa H, Fusayasu E, Ijiri T, et al. Association of the insertion/deletion polymorphism of the angiotensin I-converting enzyme gene in patients of migraine with aura. Neurosci Lett 2005;374(2):129-31
   PubMed Web of Science ®Google Scholar
• Horasanlı B, Ataç FB, Çöven I, et al. Angiotensin I-converting enzyme gene (I/D) polymorphism in patients with migraine. Headache 2013;53(1):161-4
   PubMed Web of Science ®Google Scholar
• Joshi G, Pradhan S, Mittal B. Role of the ACE ID and MTHFR C677T polymorphisms in genetic susceptibility of migraine in a north Indian population. J Neurol Sci 2009;277(1-2):133-7
   PubMed Web of Science ®Google Scholar
• Kara I, Ozkok E, Aydin M, et al. Combined effects of ACE and MMP-3 polymorphisms on migraine development. Cephalalgia 2007;27(3):235-43
   PubMed Web of Science ®Google Scholar
• Lin JJ, Wang PJ, Chen CH, et al. Homozygous deletion genotype of angiotensin converting enzyme confers protection against migraine in man. Acta Neurol Taiwan 2005;14(3):120-5
   PubMedGoogle Scholar
• Tronvik E, Stovner LJ, Bovim G, et al. Angiotensin-converting enzyme gene insertion/deletion polymorphism in migraine patients. BMC Neurol 2008;8:4
   PubMed Web of Science ®Google Scholar
• Schürks M, Zee RY, Buring JE, Kurth T. ACE D/I polymorphism, migraine, and cardiovascular disease in women. Neurology 2009;72(7):650-6
   PubMedGoogle Scholar
• Cakmak EA, Cataloluk O, Yoldas T, et al. Migraine and angiotensin-converting enzyme association in Turkish patients. Pain Clinic 2003;15(4):473-7
   Web of Science ®Google Scholar
• Schürks M, Zee RY, Buring JE, Kurth T. MTHFR 677C->T and ACE D/I polymorphisms and migraine attack frequency in women. Cephalalgia 2010;30(4):447-56
   PubMedGoogle Scholar
• Etminan M, Levine MA, Tomlinson G, Rochon PA. Efficacy of angiotensin II receptor antagonists in preventing headache: a systematic overview and meta-analysis. Am J Med 2002;112(8):642-6
   PubMedGoogle Scholar
• Onder G, Pahor M, Gambassi G, et al. Association between ACE inhibitors use and headache caused by nitrates among hypertensive patients: results from the Italian group of pharmacoepidemiology in the elderly (GIFA). Cephalalgia 2003;23(9):901-16
   PubMedGoogle Scholar
• Rahimtoola H, Buurma H, Tijssen CC, et al. Reduction in the therapeutic intensity of abortive migraine drug use during ACE inhibition therapy-a pilot study. Pharmacoepidemiol Drug Saf 2004;13(1):41-7
   PubMedGoogle Scholar
• Wang SJ, Chen PK, Fuh JL. Comorbidities of migraine. Front Neurol 2010;1:16
   PubMedGoogle Scholar
• Mancia G, Agabiti Rosei E, Ambrosioni E, et al. Hypertension and migraine comorbidity: prevalence and risk of cerebrovascular events: evidence from a large, multicenter, cross-sectional survey in Italy (MIRACLES study). J Hypertens 2011;29(2):309-18
   PubMedGoogle Scholar
• Sacco S, Cerone D, Carolei A. Comorbid neuropathologies in migraine: an update on cerebrovascular and cardiovascular aspects. J Headache Pain 2008;9(4):237-48
   PubMedGoogle Scholar
• Murphy AZ, Ennis M, Rizvi TA, et al. Fos expression induced by changes in arterial pressure is localized in distinct, longitudinally organized columns of neurons in the rat midbrain periaqueductal gray. J Comp Neurol 1995;360(2):286-300
   PubMedGoogle Scholar
• Baldi E, Conti P, Conti R, et al. Hypernociceptive syndromes and pharmacological inhibition of endogenous opioid degradation. Int J Clin Pharmacol Res 1986;6(3):193-7
   PubMedGoogle Scholar
• Paterna S, di Pasquale P, Martino S, et al. Captopril versus placebo in the prevention of hemicrania without aura. A randomized double-blind study. Clin Ter 1992;141(12):475-81
   PubMedGoogle Scholar
• Montastruc P, Dang-Tran L, Carvajal A, et al. Naloxone reverses the effects of enalapril and enalaprilic acid on the pressor responses to afferent vagal stimulation. Neuropeptides 1985;6(6):537-42
   PubMedGoogle Scholar
• Pacurari M, Kafoury R, Tchounwou PB, Ndebele K. The Renin-Angiotensin-aldosterone system in vascular inflammation and remodeling. Int J Inflam 2014;2014:689360
   PubMedGoogle Scholar
• Shahin Y, Khan JA, Samuel N, Chetter I. Angiotensin converting enzyme inhibitors effect on endothelial dysfunction: a meta-analysis of randomised controlled trials. Atherosclerosis 2011;216(1):7-16
   PubMed Web of Science ®Google Scholar
• Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342(3):145-53
   PubMed Web of Science ®Google Scholar
• Kurth T, Diener HC, Buring JE. Migraine and cardiovascular disease in women and the role of aspirin: subgroup analyses in the Women’s Health Study. Cephalalgia 2011;31(10):1106-15
   PubMedGoogle Scholar
• Sacco S, Olivieri L, Bastianello S, Carolei A. Comorbid neuropathologies in migraine. J Headache Pain 2006;7(4):222-30
   PubMedGoogle Scholar
• Sacco S, Ricci S, Carolei A. Migraine and vascular diseases: a review of the evidence and potential implications for management. Cephalalgia 2012;32(10):785-95
   PubMedGoogle Scholar
• Sacco S, Ornello R, Ripa P, et al. Migraine and hemorrhagic stroke: a meta-analysis. Stroke 2013;44(11):3032-8
   PubMed Web of Science ®Google Scholar
• Verdecchia P, Angeli F, Mazzotta G, et al. The renin angiotensin system in the development of cardiovascular disease: role of aliskiren in risk reduction. Vasc Health Risk Manag 2008;4(5):971-81
   PubMedGoogle Scholar
• Higashi Y, Chayama K, Yoshizumi M. Angiotensin II type I receptor blocker and endothelial function in humans: role of nitric oxide and oxidative stress. Curr Med Chem Cardiovasc Hematol Agents 2005;3(2):133-48
   PubMedGoogle Scholar
• Neutel JM. Effect of the renin-angiotensin system on the vessel wall: using ACE inhibition to improve endothelial function. J Hum Hypertens 2004;18(9):599-606
   PubMedGoogle Scholar
• Javanmard SH, Sonbolestan SA, Heshmat-Ghahdarijani K, et al. Enalapril improves endothelial function in patients with migraine: a randomized, double-blind, placebo-controlled trial. J Res Med Sci 2011;16(1):26-32
   PubMedGoogle Scholar
• Napoli R, Guardasole V, Zarra E, et al. Vascular smooth muscle cell dysfunction in patients with migraine. Neurology 2009;72(24):2111-14
   PubMedGoogle Scholar
• Bot I, van Berkel TJ, Biessen EA. Mast cells: pivotal players in cardiovascular diseases. Curr Cardiol Rev 2008;4(3):170-8
   PubMedGoogle Scholar
• He A, Shi GP. Mast cell chymase and tryptase as targets for cardiovascular and metabolic diseases. Curr Pharm Des 2013;19(6):1114-25
   PubMedGoogle Scholar
• Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002;359(9311):995-1003
   PubMed Web of Science ®Google Scholar